FDA Allows Off-Label Promotion, Sort of.

In two new Guidance documents released this week, FDA presents a detailed explanation of its requirements for advertisement of approved products. In a slight policy shift, FDA walks away from the rigid enforcement of approved labels and provides some flexibility in marketing communications, while maintaining its control over new uses of approved products. The Guidance … Read more

What Does a “Modernized” FDA Mean for Drug Industry?

FDA leadership believes it can do better at reviewing new drugs by reorganizing its review divisions’ personnel and moving to centralized project management. This week FDA announced details about the planned modernization of the Office of New Drugs (OND) at the Center for Drugs (CDER). Four of the six steps proposed to modernize are incremental … Read more

FDA Wants IRBs to Write Better SOPs

In a joint announcement, FDA and Office of Human Research Protection (OHRP) at NIH released a new guidance document today to address several deficiencies observed in the SOPs and other policy and practices documents maintained by IRBs. In all, FDA and OHRP listed 55 SOPs or written policies covering 5 major areas of compliance that … Read more

No You Cannot Manufacture Pesticides and Drugs With the Same Machine.

A Florida facility was found to manufacture pesticides and human pharmaceuticals using the same equipment leading to contamination of the drugs with pesticides as found by FDA auditors during a GMP inspection. The cardinal rule for GMP is “do no harm”, and the first place you control is contamination with unwanted ingredients. So it is … Read more